- Home
- SPPP vs KOD Comparison
SPPP vs KOD Comparison
Compare SPPP & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- KOD
- Stock Information
- Founded
- SPPP 2011
- KOD 2009
- Country
- SPPP Canada
- KOD United States
- Employees
- SPPP N/A
- KOD N/A
- Industry
- SPPP
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPPP
- KOD Health Care
- Exchange
- SPPP NYSE
- KOD Nasdaq
- Market Cap
- SPPP 172.2M
- KOD 198.4M
- IPO Year
- SPPP N/A
- KOD 2018
- Fundamental
- Price
- SPPP $12.95
- KOD $5.52
- Analyst Decision
- SPPP
- KOD Hold
- Analyst Count
- SPPP 0
- KOD 3
- Target Price
- SPPP N/A
- KOD $9.00
- AVG Volume (30 Days)
- SPPP 183.3K
- KOD 385.3K
- Earning Date
- SPPP 01-01-0001
- KOD 08-13-2025
- Dividend Yield
- SPPP N/A
- KOD N/A
- EPS Growth
- SPPP N/A
- KOD N/A
- EPS
- SPPP N/A
- KOD N/A
- Revenue
- SPPP N/A
- KOD N/A
- Revenue This Year
- SPPP N/A
- KOD N/A
- Revenue Next Year
- SPPP N/A
- KOD N/A
- P/E Ratio
- SPPP N/A
- KOD N/A
- Revenue Growth
- SPPP N/A
- KOD N/A
- 52 Week Low
- SPPP $8.55
- KOD $1.92
- 52 Week High
- SPPP $11.39
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- SPPP 66.96
- KOD 72.44
- Support Level
- SPPP $11.57
- KOD $4.39
- Resistance Level
- SPPP $12.68
- KOD $5.33
- Average True Range (ATR)
- SPPP 0.28
- KOD 0.41
- MACD
- SPPP 0.05
- KOD 0.15
- Stochastic Oscillator
- SPPP 77.97
- KOD 95.52
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.